Feedback
Settings

Settings

Goto Application

3,363 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16H* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 337
1.WO/2021/247682METHODS FOR MITIGATING OR DIMINISHING SPREAD OF PATHOGENIC INFECTIONS
WO - 09.12.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
 Appl.No PCT/US2021/035421 Applicant ROSS, Peter M. Inventor ROSS, Peter M.
The present methods comprise initial administration of a first rapid test, such as rapid antigen test, that has a low likelihood of false positive results and a known likelihood of false negative results, alone or in conjunction with other rapid tests, to identify a first subpopulation of positives, to which an infection mitigation protocol (such as quarantine or the administration of a therapeutic treatment) is administered. Negatives are recorded and provisionally released from further study. A diagnostic test is then administered to this subpopulation, to identify the portion of this first subpopulation that were false positives in the first test. Ideally, a positive result for the diagnostic test is pathognomonic for the infection. Any infection mitigation protocol (such as quarantine) may then be discontinued for those testing negative in the first population and intensified for those testing positive, such as with contact tracing or other protocols, to identify all true positives and those they may have infected within the population.
2.WO/2021/237292METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
WO - 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No PCT/AU2021/050507 Applicant GENETIC TECHNOLOGIES LIMITED Inventor DITE, Gillian Sue
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection.
3.20210290970ILLUMINATION DEVICES FOR INDUCING BIOLOGICAL EFFECTS
US - 23.09.2021
Int.Class A61N 5/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
06using light
 Appl.No 17162259 Applicant KNOW Bio, LLC Inventor F. Neal Hunter

Illumination devices for impinging light on tissue, for example within a body cavity of a patient, to induce various biological effects are disclosed. Biological effects may include at least one of inactivating and/or inhibiting growth of one or more pathogens, upregulating a local immune response, increasing endogenous stores of nitric oxide, releasing nitric oxide from endogenous stores, and inducing an anti-inflammatory effect. Wavelengths of light are selected based on intended biological effects for one or more of targeted tissue types and targeted pathogens. Light treatments may provide multiple pathogenic biological effects, either with light of a single wavelength or with light having multiple wavelengths. Devices for light treatments are disclosed that provide light doses for inducing biological effects on various targeted pathogens and tissues with increased efficacy and reduced cytotoxicity. Illumination devices may be configured to communicate with networks and/or servers to provide control and/or management of phototherapy treatments.

4.202341003004Early Diagnosis and Preventive Mechanism for Covid19 to Cardiac Patients
IN - 20.01.2023
Int.Class A61B /
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
 Appl.No 202341003004 Applicant R.Balakrishna Inventor Dr Balakrishna R
Early Diagnosis and Preventive Mechanism for COVI19 to CARDIAC Patients proposed system will be implemented to monitor Cardiac patients and to collect the critical health parameters in order to identify the COVID-19 in its early stages. The ranges of critical parameter values are compared with the data available in the online repository. Three different levels of threshold values are used in the analysis to classify the stage 1, stage 2 and stage 3. Using three stages of analysis and threshold values preventive measures and the treatment plan is identified. The machine learning technique used in this proposed system will enhance the prediction accuracy. This system will enable quick decision making and also provides alert to the physician to give treatment in an early stage of COVID-19 and this system will support to save the life of cardiac patients in this pandemic situations.
5.WO/2021/191829ASSAYS FOR DETECTING PATHOGENS
WO - 30.09.2021
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
 Appl.No PCT/IB2021/052463 Applicant ANGSTROM BIO, INC. Inventor SANTOS, Carlos F.
Provided herein are compositions and methods for identifying target nucleic acids that are determinants of pathogenic infections. The multiplexed methods provided herein simultaneously detect target proteins such as IgG and IgM immunoglobulins that are indicative of one or more pathogenic infections, from several distinct biological samples. Also provided herein are methods for detecting sequence variants in a nucleic acid sample.
6.2020103841A SYSTEM AND A METHOD FOR QUARANTINE EPIDEMIC MODELS
AU - 24.12.2020
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
 Appl.No 2020103841 Applicant Kumar Keshri, Ajit Inventor Kumar Keshri, Ajit
The present disclosure relates to a system and a method for quarantine epidemic models. The disclosed system facilitates three quarantine models of pandemic which accounts the compartments including susceptible population, immigrant population, home isolation population, infectious population, hospital quarantine population, and recovered population. Local and global asymptotic stability is proved for all the three models. Extensive numerical simulations are performed to establish the analytical results with suitable examples. The system discloses that home isolation and quarantine to hospitals are the two-pivot force-control policies under the present situation when no treatment is available for this pandemic.
7.WO/2022/148828A SYSTEM, A NON-VOLATILE MEMORY AND A METHOD FOR COLLECTING TEST DATA RELATING TO A PATHOGEN
WO - 14.07.2022
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
 Appl.No PCT/EP2022/050238 Applicant WOLFS, Marijana Inventor WOLFS, Marijana
The present invention provides a system for collecting test data indicative of a test for a pathogen in a subject, comprising: a testing unit provided with an identification of the test, wherein the testing unit is configured to determine the presence of the pathogen because of the test. The system further comprises a clock configured to generate a time stamp for the test, a position determination unit configured to provide geographic location information of the test, a processing unit configured to collect the test data comprising the identification, the time stamp and the geographic location information as well as the result of the test, and a communication unit configured to transmit the test data to a predefined destination.
8.WO/2021/236288INTELLIGENT WORKFLOW ANALYSIS FOR TREATING COVID-19 USING EXPOSABLE CLOUD-BASED REGISTRIES
WO - 25.11.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
 Appl.No PCT/US2021/028647 Applicant HOFFMANN-LA ROCHE INC. Inventor MOLERO LEON, Silvia Elena
Disclosed herein are systems, methods, and techniques for building and using a data platform to facilitate intelligent identification of coronavirus disease 2019 (COVID-19) related diagnoses, treatment selection, and interaction tracing. The present disclosure relates to a cloud-based application that generates outputs predictive of a subject's COVID-19 diagnoses and/or suitability for COVID-19 treatments.
9.WO/2022/174287METHODS AND SYSTEMS FOR DETECTING A CORONAVIRUS INFECTION
WO - 25.08.2022
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No PCT/AU2022/050105 Applicant COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION Inventor STEWART, Cameron
The present disclosure relates to methods, kits, and panels for determining the likelihood of a coronavirus (CoV) infection or a severe coronavirus (CoV) infection in a subject, such as a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus infection. The disclosure also relates to methods for monitoring CoV or severe CoV infection in a subject.
10.20230393124Methods and Systems for Quantitative Detection of SARS-CoV-2 Antibodies Using Dried Samples
US - 07.12.2023
Int.Class G01N 33/533
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
533with fluorescent label
 Appl.No 18205255 Applicant Laboratory Corporation of America Holdings Inventor Russell Philip Grant

In certain aspects, disclosed are methods and systems for detecting SARS-CoV-2 analytes in dried samples, as for example, dried blood spots. For example, disclosed are methods for measuring an antibody to SARS-CoV-2 in a dried sample that include the steps of: (a) obtaining a dried sample from a subject; (b) extracting the SARS-COV-2 antibody from the dried sample; and (c) detecting the SARS-COV-2 antibody extracted from the dried sample. In certain embodiments, the method is semi-quantitative. The method may, in certain embodiments, further comprise obtaining measurements from an individual over a period of time to follow the titer of SARS-CoV-2 antibody in the individual. For example, the titer may be followed in the individual for at least 19 weeks or longer.

# -